<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">
    <channel>
        <image>
            <title>freepatentsonline.com</title>
            <width>141</width>
            <height>131</height>
            <link>http://www.freepatentsonline.com/</link>
            <url>http://www.freepatentsonline.com/images/logo.gif</url>
        </image>
        
        <title>Free Patents Online: Chemistry: molecular biology and microbiology</title>
        <link>http://www.freepatentsonline.com/rssfeed/rssapp435.xml</link>
        <description>USPTO Class 435 Chemistry: molecular biology and microbiology</description>
        <language>en-us</language>
        <lastBuildDate>Thu, 09 Feb 2012 08:00:00 EST</lastBuildDate>
        <item>
            <title><![CDATA[Broccoli Type Adapted for Ease of Harvest]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036601.html</link>
            <description><![CDATA[A broccoli plant characterized in having an exerted head having a crown higher than the leaf canopy and a harvestable head of at least about 200 grams when planted at a density of 40,000 plants per hectare, where the harvestable head comprises the top 25 centimeters of said stalk.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR GENERATING HYPOALLERGENIC GLYCOPROTEINS IN MUTATED OR TRANSGENIC PLANTS OR PLANT CELLS, AND MUTATED OR TRANSGENIC PLANTS AND PLANT CELLS FOR GENERATING HYPOALLERGENIC GLYCOPROTEINS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036600.html</link>
            <description><![CDATA[Method for providing a hypoallergenic glycoprotein includes growing at least one of a mutated plant, a part of the mutated plant, plant cells produced from the mutated plant, a transgenic plant, a part of the transgenic plant and plant cells produced from the transgenic plant wherein an activity of an enzyme Golgi α-mannosidase II has been eliminated or decreased so as to obtain a grown material. The hypoallergenic glycoprotein is isolated from the grown material.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL FUNGAL ENZYMES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036599.html</link>
            <description><![CDATA[This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method to convert lignocellulosic biomass to fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. The invention also relates to methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, deinking and biobleaching of paper and pulp, and treatment of waste streams.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Cold-Tolerant Plants]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036597.html</link>
            <description><![CDATA[Disclosed are chill- or cold-tolerant plants and methods of making the plants. Also disclosed are methods for identifying a plant that is tolerant to chill.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MAMMALIAN-TYPE GLYCOSYLATION IN PLANTS BY EXPRESSION OF NON-MAMMALIAN GLYCOSYLTRANSFERASES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036596.html</link>
            <description><![CDATA[The present invention relates to non-mammalian β-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian β-1,4-galacto-syltransferase and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation. The invention additionally provides nucleic acid molecules and expression vectors of non-mammalian β-1,4-galactosyltransferases.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Whole Seed Specific Promoter]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036595.html</link>
            <description><![CDATA[The present invention is concerned with the provision of means and methods for gene expression. Specifically, it relates to a polynucleotide comprising an expression control sequence which allows for seed specific of a nucleic acid of interest being operatively linked thereto in plants. Furthermore, vectors, host cells, transgenic plants and methods for expressing nucleic acids of interest are provided which are based on the said polynucleotide.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[RNA-Mediated Induction of Gene Expression in Plants]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036594.html</link>
            <description><![CDATA[The present invention is in the field of plant genetics and provides methods for increasing gene expression of a target gene in a plant or part thereof. In addition the invention relates to methods for modifying the specificity of plant specific promoters and for engineering small non-coding activating RNA (sncaRNA) in order to increase expression of a target gene in a plant or part thereof. The present invention also provides methods for the identification of sncaRNA, and its primary transcripts in a plant capable of increasing gene expression in a plant or part thereof.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Plant Promoter Operable in Endosperm and Uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036593.html</link>
            <description><![CDATA[The present invention provides compositions of matter comprising plant-operable promoter sequences that confer selective/specific endosperm expression on genes to which they are operably connected and uses of such compositions to confer gene expression, especially in developing endosperm.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Process for Producing a Hybrid Maize Having Insulated Casing and Individual Shield for Grains, by Means of a Genetic Tool, and a Hybrid Maize Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036592.html</link>
            <description><![CDATA[A process for the generation of hybrid maize whose grains are differentiated and preserved by entirely covering their surfaces, isolating the entire endosperm from the outside and conserving all the nutritious and germinative characteristics from the parentals; and the maize produced by the process.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR MITOCHONDRIAL DNA REPLACEMENT IN OOCYTES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036591.html</link>
            <description><![CDATA[Methods are provided for producing a primate oocyte in vitro. The methods include removing nuclear DNA from a recipient primate oocyte from a first primate in a manner that does not lower levels of maturation promoting factor (MPF) to form an enucleated recipient primate oocyte. The recipient primate oocyte is enucleated using a non-UV-based spindle imaging system. Nuclear genetic material or DNA including chromosomes from a donor primate oocyte arrested at metaphase II from a second primate is isolated in the form of the karyoplast and introduced into the enucleated recipient primate oocyte. Introduction of the chromosomes is performed using a fusogenic agent or electroporation to produce a hybrid oocyte.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[VACCINE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036589.html</link>
            <description><![CDATA[The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROSTATE CANCER CELL LINES AND THEIR USE IN SCREENING METHOD]]></title>
            <link>http://www.freepatentsonline.com/y2012/0036587.html</link>
            <description><![CDATA[The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[URINE SAMPLE TESTING APPARATUS AND APPARATUS FOR PROCESSING MEASUREMENT RESULT OF URINE SAMPLE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035879.html</link>
            <description><![CDATA[A urine sample testing apparatus comprises: a urine qualitative measuring section configured to acquire a measurement result for each of a plurality of urine qualitative measurement items; a urine sediment measuring section configured to acquire a measurement result for each of a plurality of urine sediment measurement items; an operation part that is operable by a user to specify a combination of one of the plurality of urine qualitative measurement items and one of the plurality of urine sediment measurement items; an information processing unit configured to determine whether or not a first measurement result of the urine sample obtained by the urine qualitative measuring section and a second measurement result of the urine sample obtained by the urine sediment measuring section have a predetermined relationship with respect to the urine qualitative measurement item and the urine sediment measurement item included in the specified combination.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods, Devices and Systems for Bone Tissue Engineering Using a Bioreactor]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035742.html</link>
            <description><![CDATA[An anatomically-shaped, human bone graft may be cultivated ex vivo using a bioreactor capable of perfusing large complex porous scaffolds. Scaffolds derived from image-based modeling of a target are seeded with human mesenchymal stem cells and cultivated. A bioreactor configured to house complex three-dimensional scaffold geometries provides controlled flow for perfusion of the cells. Dense uniform cellular growth can be attained throughout the entire scaffold as a result of the medium perfusion. In an embodiment, the bioreactor has a mold into which perfusion medium is pumped under pressure and multiple ports through which the medium exits the mold.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Electromagnetic treatment of tissues and cells]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035608.html</link>
            <description><![CDATA[Provided herein are methods, devices and compositions to conductively or to inductively fix substrates, including tissues, using electromagnetic energy. Also provided is a method of controlling the fixing process via feedback monitoring of a property of the composition and/or of the electromagnetic energy used.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[POLYNUCLEOTIDE ENCODING A NOVEL HUMAN P2X7 SPLICE VARIANT, HBMYP2X7V]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035350.html</link>
            <description><![CDATA[The present invention provides novel polynucleotides encoding HBMYP2X7v polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HBMYP2X7v polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[INTERFERON-ALFA SENSITIVITY BIOMARKERS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035347.html</link>
            <description><![CDATA[The present invention provides biomarkers of sensitivity to interferon alfa (IFN-α). These IFN-α sensitivity biomarkers are useful, inter alia, to identify patients who are most likely to benefit from treatment with pharmaceutical compositions of IFN-α, in methods of treating patients having a disease susceptible to treatment with interferon alfa, and in methods for selecting the most appropriate therapy for such patients.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035320.html</link>
            <description><![CDATA[The present invention provides nucleic acid delivery polyplex complexes and anionic open polyplexes comprising a nucleic acid molecule reversibly bound to one or more of nucleic acid delivery polyplex complexes.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROTOCOL FOR SCREENING TRAVELERS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035279.html</link>
            <description><![CDATA[Methods for screening a traveler for an evaluation of the traveler's physical condition or health status by obtaining at least one specimen from the traveler and subjecting the specimen to at least one test that is diagnostic for at least one parameter of the physical condition or health status of the traveler prior to or while the traveler undertakes a journey. Thereafter, the results of the diagnostic test are reported prior to or contemporaneous with the arrival of the traveler at the traveler's destination.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[TISSUE REGENERATIVE COMPOSITION, METHOD OF MAKING, AND METHOD OF USE THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035276.html</link>
            <description><![CDATA[A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SPHINGO-GUANIDINES AND THEIR USE AS INHIBITORS OF SPHINGOSINE KINASE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035268.html</link>
            <description><![CDATA[The presently disclosed subject matter provides compounds of the formula: (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods for making the compounds of the formula as set forth hereinabove, their use in inhibiting sphingosine kinase, and their use in the treatment and/or prevention of diseases and/or conditions associated with undesirable ceramidase or sphingosine kinase activity, including, but not limit cancer, cancer metastasis, atherosclerosis, stenosis, inflammation, immunological disorders, asthma, atopic dermatitis, wound healing, and other proliferative diseases.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035246.html</link>
            <description><![CDATA[Provided is a novel nucleic acid molecule that can be produced easily and efficiently and can inhibit the expression of a gene. The nucleic acid molecule is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes: a region (X); a linker region (Lx); and a region (Xc). The linker region (Lx) is linked between the regions (Xc) and (Xc). The region (Xc) is complementary to the region (X). At least one of the regions (X) and (Xc) includes the expression inhibitory sequence. The linker region (Lx) has a non-nucleotide structure including at least one of a pyrrolidine skeleton and a piperidine skeleton. According to this single-stranded nucleic acid molecule, it is possible to inhibit the expression of the target gene.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING INFLAMMATION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035245.html</link>
            <description><![CDATA[The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the stabilization of mast cells, in particular that inhibit mast cell degranulation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by mast cell degranulation and/or inflammation, including allergic rhinitis.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PARP1 TARGETED THERAPY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035244.html</link>
            <description><![CDATA[The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to PARP1 proteins and nucleic acids as clinical and research targets for cancer.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[USE OF INHIBITORS OF PLAC8 ACTIVITY FOR THE MODULATION OF ADIPOGENESIS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035241.html</link>
            <description><![CDATA[The present invention concerns Plac8, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Plac8 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Plac8 activity as well screening test for identification of modulators as of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035240.html</link>
            <description><![CDATA[Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035215.html</link>
            <description><![CDATA[The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035208.html</link>
            <description><![CDATA[Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[GRISEOFULVIN ANALOGUES FOR THE TREATMENT OF CANCER BY INHIBITION OF CENTROSOMAL CLUSTERING]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035200.html</link>
            <description><![CDATA[The invention relates to compounds of the formula (I), where the symbols have the meaning given in the specification, for use in a method for treating cancer, to use of these compounds for the manufacture of a pharmaceutical composition for the treatment of cancer, and to methods of treatment for said diseases employing a compound of formula (I).]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Antiviral Compounds and Methods of Using Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035198.html</link>
            <description><![CDATA[Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR INDUCING TUMOR REGRESSION, INHIBITING TUMOR GROWTH, AND INDUCING APOPTOSIS IN BREAST TUMORS WITH GERANYLGERANYLTRANSFERASE I INHIBITORS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035184.html</link>
            <description><![CDATA[Methods of inducing tumor regression, inhibiting tumor growth, and inducing apoptosis with selective peptidomimetic inhibitors of geranylgeranyltransferase I (GGTase I), are provided. In one aspect, GGTI-2418 and its methylester GGTI-2417, increase levels of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 and induce breast tumor regression in vivo. In another aspect, GGTI-2417 inhibits the Cdk2-mediated phosphorylation of p27Kip1 at Thr187 and accumulates p27Kip1 in the nucleus.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035179.html</link>
            <description><![CDATA[The present invention provides compounds of Formula I useful as modulators of ABC transporter activity, or a pharmaceutically acceptable salt thereof, wherein RB, n, B, RC, RD, RE, A, and Z are described generally and in classes and subclasses below.The present invention also provides pharmaceutical compositions, methods and kits associated with Formula I, useful for as modulators, and for the treatments of disease and disease conditions associated with ABC transporter proteins.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Novel Compositions and Methods of Treating Diseases Using the Same]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035161.html</link>
            <description><![CDATA[The invention includes compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, treating diseases associated with activated lymphocytes, or treating PAH.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Modulators of Cellular Adhesion]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035154.html</link>
            <description><![CDATA[The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[BORON-CONTAINING SMALL MOLECULES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035132.html</link>
            <description><![CDATA[Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[POLYSACCHARIDE DERIVATIVE AND HYDROGEL THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035128.html</link>
            <description><![CDATA[Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C1-10 hydrocarbon group, Y is a polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R2, with R2 being a C1-23 hydrocarbon group. The hydrogel has excellent viscoelasticity and can be injected into a predetermined location with an injection device such as a syringe, and thus can be advantageously used as a medical gel or an adhesion barrier.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Extracts and Compounds from Ficus Benghalensis for Increasing Hair Growth and Decreasing Hair Loss]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035119.html</link>
            <description><![CDATA[This application discloses natural product extracts and compounds from an aerial root of a Ficus plant, such as Ficus benghalensis. The application also discloses the use of natural product extracts and compounds from Ficus plants for increasing hair growth and decreasing hair loss. Synthetic formulations comprising various compounds identified in the natural product extracts and methods of use thereof are further disclosed.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[NEURONAL DIFFERENTIATION-INDUCING PEPTIDE AND USE THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035112.html</link>
            <description><![CDATA[A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035110.html</link>
            <description><![CDATA[Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SATIATION PEPTIDE ADMINISTRATION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035100.html</link>
            <description><![CDATA[Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL ANTIVIRAL AGENT]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035098.html</link>
            <description><![CDATA[The present invention describes the use of a composition including or constituted by at least one element chosen from: a specific protein including or consisting of the amino acid sequence SEQ ID NO: 5, anda protein homologous to the specific protein, for the preparation of a medicament intended for the prevention or treatment of pathologies associated with a viral infection or an inflammation.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[GENOTOXICITY TESTING]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035079.html</link>
            <description><![CDATA[The present invention relates to methods for detecting for the presence of an agent that putatively causes or potentiates DNA damage comprising subjecting a cell (containing a DNA sequence encoding Gaussia luciferase (GLuc) reporter protein operatively linked to a human GADD45α gene promoter and a human GADD45α gene regulatory element arranged to activate expression of the DNA sequence in response to DNA damage) to an agent; and monitoring the expression of the GLuc reporter protein from the cell. The invention also concerns expression cassettes, vectors and cells which may be used according to such a method and also modified media that may be employed in assays and in preferred embodiments of the method of the invention.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ENGINEERING COMPLEX MICROBIAL PHENOTYPES WITH TRANSCRIPTION ENHANCEMENT]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035078.html</link>
            <description><![CDATA[The present invention relates to a recombinant E. coli exhibiting a complex phenotype, comprising one or more RNA polymerase subunit genes, one or more functional genes, and, optionally, one or more transcription factors from a heterologous prokaryote. Also provided are methods for screening such a recombinant E. coli.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Modified renilla luciferase nucleic acids and methods of use]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035077.html</link>
            <description><![CDATA[This invention provides modified nucleotide sequences encoding luciferase that have greater expression than wild type luciferase.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[IRAK KINASE FAMILY AS NOVEL TARGET AND BIOMARKER FOR ALZHEIMER]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035076.html</link>
            <description><![CDATA[The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS TO DETERMINE ATHEROSCLEROSIS REGRESSION, PLAQUE STABILIZTION AND CARDIOVASCULAR RISK]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035074.html</link>
            <description><![CDATA[Provided herein are compositions and methods for examining the progression, regression or risk of individuals at risk for developing coronary artery disease (CAD).]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035073.html</link>
            <description><![CDATA[The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[KASPP (LRRK2) GENE, ITS PRODUCTION AND USE FOR THE DETECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035072.html</link>
            <description><![CDATA[The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE PROBES AND PRIMERS FOR DETECTION OF MICROORGANISMS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035071.html</link>
            <description><![CDATA[Compositions and methods for the detection of vancomycin-resistant pathogens using primers and/or probes to the vanA and vanB genes.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035070.html</link>
            <description><![CDATA[There has been a need for coelenterazine analogs that exhibit luminescence properties different from those of known coelenterazine analogs. The present invention provides the compound represented by general formula (1).]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROGNOSIS OF BREAST CANCER PATIENTS BY MONITORING THE EXPRESSION OF TWO GENES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035069.html</link>
            <description><![CDATA[The present invention relates to the expression of two genes, CyclinG2 and Sharp1, which correlates with prognosis in individuals having breast cancer. Specifically, this invention provides a method to stratify samples from breast cancer patients in a high or low recurrence risk in the years following primary tumor removal. This classification can be achieved through the analysis of protein or mRNA expression levels for the two identified genes. The invention also illustrates how CyclinG2 and Sharp1 have been identified in mammary cancer cell lines and validated in a large cohort of human patients as powerful metastasis predictors.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[USE OF MIRCO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035068.html</link>
            <description><![CDATA[Methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample are disclosed. Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035067.html</link>
            <description><![CDATA[The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Aptamer Regulated Nucleic Acids and Uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035065.html</link>
            <description><![CDATA[The invention relates to aptamer-regulated, ligand-responsive nucleic acids, or “ampliSwitches,” and uses thereof. Particular embodiments include a ligand-responsive nucleic acid that comprises a primer sequence domain and an aptamer domain that is responsive to a ligand.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ALTERNATIVE NUCLEOTIDE FLOWS IN SEQUENCING-BY-SYNTHESIS METHODS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035062.html</link>
            <description><![CDATA[A method for sequencing a polynucleotide strand by using sequencing-by-synthesis techniques. To address the problem of incomplete extension (IE) and/or carry forward (CF) errors that can occur in sequencing-by-synthesis reactions, an alternative flow ordering of dNTPs is used. In contrast to conventional flow orderings, the dNTPs are flowed in an ordering that is not a continuous repeat of an ordering of the four different dNTPs. This alternate flow ordering may reduce the loss of phasic synchrony in the population of template polynucleotide strands that result from IE and/or CF errors.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[HIGHLY MULTIPLEXED GENOTYPING USING LEUKOREDUCED BLOOD SAMPLES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0035060.html</link>
            <description><![CDATA[Described herein are methods and kits useful for the extraction and analysis of genomic DNA from leukoreduced blood or plasma samples.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS AND METHODS FOR INCREASING OIL CONTENT IN ALGAE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034698.html</link>
            <description><![CDATA[The present invention provides methods and compositions for increasing oil content in algae. More particularly, the present invention relates to enhancement of phytohormone activity in algae, by genetic transformation thereof or by supplementing the algal growth medium with phytohormones, to maximize the production of oil within the algae cells.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[IN VITRO METHODS FOR THE INDUCTION AND MAINTENANCE OF PLANT CELL LINES AS SINGLE SUSPENSION CELLS WITH INTACT CELL WALLS, AND TRANSFORMATION THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034697.html</link>
            <description><![CDATA[The subject invention provides simple and consistent methods to break suspension cell aggregates to single cells with intact primary cell walls. The subject invention relates in part to cell separation of suspension cell aggregates cultured in medium containing pectin-degrading enzymes or tubulin de-polymerizing compounds including colchicine. The subject invention also relates to novel uses of compounds for such purposes. Another aspect of the subject invention relates to transformation of the subject, isolated cells. Such processes simplify and integrate single-cell-based transformation and selection processes into transgenic and transplastomic event-generation work processes. The subject invention also removes technical constraints and produces marker-free and uniformly expressing transgenic lines in a high throughput fashion to support various needs of animal health, biopharma, and trait and crop protection platforms.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034696.html</link>
            <description><![CDATA[Particular aspects provide compositions comprising an electrokinetically altered oxygenated aqueous fluid, wherein the oxygen in the fluid is present in an amount of at least 25 ppm. In certain aspects, the electrokinetically altered oxygenated aqueous fluid comprises electrokinetically modified or charged oxygen species present in an amount of at least 0.5 ppm. In certain aspects the electrokinetically altered oxygenated aqueous fluid comprises solvated electrons stabilized by molecular oxygen, and wherein the solvated electrons present in an amount of at least 0.01 ppm. In certain aspects, the fluid facilitates oxidation of pyrogallol to purpurogallin in the presence of horseradish peroxidase enzyme (HRP) in an amount above that afforded by a control pressure pot generated or fine-bubble generated aqueous fluid having an equivalent dissolved oxygen level, and wherein there is no hydrogen peroxide, or less than 0.1 ppm of hydrogen peroxide present in the electrokinetic oxygen-enriched aqueous fluid.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[TISSUE/CELL CULTURING SYSTEM AND RELATED METHODS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034695.html</link>
            <description><![CDATA[A system for culturing cells and/or tissue includes a tissue/cell culture chamber including a tissue/cell culture membrane, at least one collapsible valve fluidly coupled with the tissue/cell culture chamber, a pump fluidly coupled with the tissue/cell culture chamber, and a flow loop including the pump, chamber, and collapsible valve fluidly coupled together.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[CELL CULTURE SUPPORT AND CELL CULTURE METHOD]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034694.html</link>
            <description><![CDATA[The present invention relates to a cell culture support for culturing mesenchymal stem cells, which includes en upper surface including a plurality of wells, in which the upper surface has a root mean square roughness Rq of 100 to 280 nm and a linear density of 1.6 to 10 per 1 μm length.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[RECOMBINANT VECTOR AND USE IN GENE THERAPY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034693.html</link>
            <description><![CDATA[A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including lentiviral regions of packaging signal (ψ, psi), LTRs, RRE, and PBS; wherein said A3G gene is operably linked to the packaging signal (ψ, psi), LTRs, RRE, and PBS.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ENDOCRINE PRECURSOR CELLS, PANCREATIC HORMONE-EXPRESSING CELLS AND METHODS OF PRODUCTION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034692.html</link>
            <description><![CDATA[Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[GENETICALLY ENCODED CALCIUM INDICATORS AND METHODS OF USE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034691.html</link>
            <description><![CDATA[Provided herein are nucleic acid sequences and polypeptides encoding a genetically encoded calcium indicator (GECI). Also provided are vectors and cells comprising the nucleic acid sequences and/or polypeptides. Kits comprising the nucleic acid sequences, polypeptides, vectors, cells and combinations thereof are also provided. Also provided herein are methods of screening for G-protein coupled receptor (GPCR) agonists and antagonists and methods of monitoring neural activity using the GECIs.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Cell lines producing blocking antibodies to human RANKL]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034690.html</link>
            <description><![CDATA[Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MYCOBACTERIAL ANTIGENS EXPRESSED DURING LATENCY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034689.html</link>
            <description><![CDATA[A method is provided for identifying mycobacterial genes that are induced or up-regulated under culture conditions that are nutrient-starving and which maintain mycobacterial latency, said conditions being obtainable by batch fermentation of a mycobacterium for at least 20 days post-inoculation, when compared with culture conditions that are not nutrient-starving and which support exponential growth of said mycobacterium. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[True nucleic acid amplification]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034688.html</link>
            <description><![CDATA[A system and method directed to DNA amplification with optional in situ purification, sequencing and/or detection, or a system compatible with integrated, post-amplification purification and or sequencing by capillary electrophoresis and other methods. The device is a single, helical channel formed of fused silica with heat zones defined about fixed arcs of the helix inner and/or outer circumference. The length of the helical channel and the cycle number and dwell time may be varied by altering the pitch of the helix within the cylindrical substrate. In another embodiment, the heat zone arcs lengths are also variable. In still another embodiment, multiple helical channels are available in parallel within the same structure. Separation channels may be integrated on the device for post-amplification purification and/or sequencing. One or more detection schemes may be provided on the device or seamlessly integrated with the device, for monitoring amplification and/or detecting specific products.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROTECTION OF BIOANALYTICAL SAMPLE CHAMBERS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034687.html</link>
            <description><![CDATA[An apparatus for performing bioanalytic processing and analysis, a bioanalytical reaction device, and a cartridge thereof are provided. The cartridge contains a housing and at least one sample chamber in a platform for storing biological samples, which the bioanalytical reaction device can process and analyze. The platform is movably connected to the housing such that the platform is movable between a stowed position, in which the sample chamber is protected by the housing, and an extended position, in which the sample chamber is outside of the housing. The bioanalytical reaction device includes an actuation device for moving the platform between the stowed and extended positions.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DEVICES AND METHODS FOR DUAL EXCITATION RAMAN SPECTROSCOPY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034686.html</link>
            <description><![CDATA[Spectroscopic analysis systems and methods for analyzing samples are disclosed. An analysis system may contain an electromagnetic radiation source to provide radiation, a spectroscopic analysis chamber to perform a coherent Raman spectroscopy (e.g., stimulated Raman or coherent anti-Stokes Raman spectroscopy), and a radiation detector to detect radiation based on the spectroscopy. The chamber may have a resonant cavity to contain a sample for analysis, at least one window to the cavity to transmit the first radiation into the cavity and to transmit a second radiation out, a plurality of reflectors affixed to a housing of the cavity to reflect radiation of a predetermined frequency, the plurality of reflectors separated by a distance that is sufficient to resonate the radiation. The spectroscopic analysis system may be coupled with a nucleic acid sequencing system to receive a single nucleic acid derivative in solution and identify the derivative to sequence the nucleic acid.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ASSAY SYSTEMS FOR DETERMINATION OF SOURCE CONTRIBUTION IN A SAMPLE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034685.html</link>
            <description><![CDATA[The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MAGNETIC IMMUNOSENSOR WITH TRENCH CONFIGURATION AND METHOD OF USE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034684.html</link>
            <description><![CDATA[The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PETROLEUM BIOCONVERSION OF ORGANIC ACIDS TO PREVENT REFINERY CORROSION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034683.html</link>
            <description><![CDATA[The present invention relates to the use of microorganisms (biocatalysts), or catalysts derived from these organisms (enzymes), to improve the quality of crude oil and bitumen as an attractive alternative to current upgrading methods. The invention identifies and characterizes the microorganism species, in particular, N. muscorum (UTEX 2209) and Kocuria rhizophilia (ATCC533), that have the capability to biochemically convert organic acids into chemical species that do not possess corrosive properties.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Process for Separating High Purity Germ and Bran from Corn]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034682.html</link>
            <description><![CDATA[A semi-wet process for refining corn to make a feedstock for ethanol production. Corn is tempered at a moisture content from about 20-25% by weight for a very short time followed by grinding. The ground corn is not dried and cooled before further processing. It is graded and then ground and sifted to make an endosperm fraction and a high purity fraction of germ and bran. The fraction of germ and bran can be separated in a one or two stage dry separation process or in a wet separation process. In the wet separation process, the fraction of germ and bran is enzymatically steeped, dewatered and then separated in hydrocyclones to produce a germ fraction and a bran fraction.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DIGESTER FOR HIGH SOLIDS WASTE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034681.html</link>
            <description><![CDATA[A digester with separate stages for hydrolysis and methanogenesis is disclosed. The digester includes a leachate bay reactor, which may be configured as modular, multi-bay units. Waste material is added to the leachate bay reactor. A leachate storage tank is fluidically connected to the leachate bay reactor, which facilitates hydrolysis. Leachate from the leachate storage tank is recirculated through the leachate bay reactor. A high rate methanogenic reactor is fluidically connected to the leachate storage tank to cycle the leachate in a fixed film environment for biogas production from solubilized organic matter. The reactor may be operated in an anaerobic digestion mode, or a dual aerobic-anaerobic digestion mode. The reactor may also include a struvite system having a crystallizer unit and a separation unit to reduce ammonium and phosphate accumulation during operation.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Process For Treating Carbon Dioxide Containing Gas]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034680.html</link>
            <description><![CDATA[A process is disclosed for recycling carbon dioxide emissions from a fossil-fuel power plant into useful carbonated species The process primarily comprises the steps of: a) burning the fossil fuel, thereby generating heat and a hot exhaust gas containing CO2; and b) converting the heat into energy. The process is characterized in that it further comprises the steps of: c) cooling the exhaust gas; and d) biologically transforming the CO2 contained in the cooled exhaust gas into carbonated species, thereby obtaining a low CO2 exhaust gas and producing useful carbonated species. The low CO2 exhaust gas obtained in step d) can be released in the atmosphere without increasing the problem of greenhouse effect.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD AND APPARATUS FOR CULTIVATION OF ALGAE AND CYANOBACTERIA]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034679.html</link>
            <description><![CDATA[The invention relates to a method of cultivation of algae or cyanobacteria in the presence of a luminous material that converts light of a first wavelength to a second wavelength more suitable for use in photosynthesis by the algae or cyanobacteria, and apparatus for performing the method. In one embodiment the apparatus (50) is of flexible plastic with fluorescent light concentrator or light guide (76) and perforated pipe (56) for bubbling carbon dioxide through the culture. The algae or cyanobacteria may be used to produce biofuels.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Diaryl Ethers]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034678.html</link>
            <description><![CDATA[Compounds of the formula I: including any possible stereoisomers thereof, or a pharmaceutically acceptable salt and/or solvate thereof, as well as pharmaceutical formulations and the use of compounds of formula I as HCV inhibitors.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MICROORGANISM CULTURE DEVICE AND METHOD OF OPERATION THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034677.html</link>
            <description><![CDATA[The invention is directed to a microorganism culture device (100), such as a micro fluidic cell culture device. The device comprises an open chamber (10), wherein microorganisms are likely to be deposited within a liquid for subsequent study. The open chamber simplifies the deposition of the microorganisms. The chamber is further provided with retention features (11), whereby microorganisms can be retained therein. In addition, the device comprises an overflow area (20), wherein capillary structures (22) are configured to retain excess liquid overflowing from the open chamber, e.g. when covering the device with a cover. As such, it allows for confining microorganism in the chamber, while excess fluid is captured externally, e.g. to seal the device with a cover.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034676.html</link>
            <description><![CDATA[The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Tyrosinase mutant and methods of use thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034675.html</link>
            <description><![CDATA[The present invention describes a novel tyrosinase protein and methods of use thereof. Specifically, the invention provides tyrosinase derived peptides and polynucleotides, and their ability to elicit an immune response and treat a melanoma.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD OF PRODUCING RECOMBINANT ADAMTS13 IN CELL CULTURE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034674.html</link>
            <description><![CDATA[Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Isolated plant deoxyhypusine synthase and nucleotides encoding same]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034673.html</link>
            <description><![CDATA[Regulation of expression of programmed cell death, including senescence, in plants is achieved by integration of a gene or gene fragment encoding senescence-induced deoxyhypusine synthase, senescence-induced eIF-5A or both into the plant genome in antisense orientation. Plant genes encoding senescence-induced deoxyhypusine synthase and senescence-induced eIF-5A are identified and the nucleotide sequences of each, alone and in combination are used to modify senescence in transgenic plants.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SUPERLUMINESCENT LUCIFERASE VARIANT WITH PROLONGED BIOLUMINESCENCE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034672.html</link>
            <description><![CDATA[This invention provides a genetically modified marine luciferase such as Gaussia luciferase, which has high bioluminescence intensity, and has high bioluminescence stability and/or red-shifted wavelength. Specifically disclosed is a luciferase variant with improved optical property obtained by replacing at least one amino acid residue among the amino acid sequence of a marine luciferase at positions corresponding to positions 89 to 118 in the amino acid sequence of Gaussia luciferase (GLuc), wherein an amino acid residue at a position corresponding to at least one selected from positions 89, 90, 95, 97, 100, 108, 112, 115, and 118 in the amino acid sequence of GLuc is replaced by way of conservative amino acid replacement. The above-mentioned replacement in a marine luciferase improves enzymatic activity of the luciferase. Also disclosed is a bioluminescent probe having an improved optical property, which is produced using the luciferase variant of the present invention.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Protein Matrix For Light-Initiated Electron Transfer]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034671.html</link>
            <description><![CDATA[The present invention provides selective modification of polypeptide sequences with electron transfer moieties. The resulting polypeptide assemblies represent a novel class of electron transfer complexes that are capable of transferring electrons over very long distances at fast rates. These complexes possess unique structural features which enable the production of bioconductors and photoactive probes.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ORGANIC-INORGANIC COMPOSITE MATERIAL AND PROCESS FOR PRODUCING SAME]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034670.html</link>
            <description><![CDATA[Disclosed is an organic-inorganic composite material obtained by chemically modifying a microorganism-derived ceramic material with an organic group, and a process for producing the organic-inorganic composite material. The process is characterized by reacting a microorganism-derived ceramic material with at least one compound selected from the group consisting of silane coupling agents represented by formula (1), silane coupling agents represented by formula (2), and titanate coupling agents represented by formula (3). The organic-inorganic complex can be used in applications for immobilized catalysts and immobilized enzyme catalysts.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS FOR PRODUCING USEFUL SUBSTANCE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034669.html</link>
            <description><![CDATA[The present invention provides a process for producing a useful substance which comprises culturing a transformant obtained by transforming a microorganism capable of producing the useful substance with a DNA encoding a protein in a medium, wherein the protein has an activity to improve growth of a high concentration oxygen-requiring microorganism under low oxygen concentration; forming and accumulating the useful substance in a culture; and collecting the useful substance from the culture.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL NITRATE REDUCTASE FUSION PROTEINS AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034668.html</link>
            <description><![CDATA[The present invention relates to a novel fusion protein comprising a nitrate reductase (NR) and a truncated hemoglobin N (trHbN) domain. The fusion protein may be used for bioremediation of nitric oxide.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR RECOVERING AND PRODUCING ETHANOL AND OIL]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034667.html</link>
            <description><![CDATA[To provide a method for producing an ethanol which facilitates the processing of a solid component as a residue generated upon processing, while improving the recovery rate of heat energy contained in leftover food. The method for recovering and producing ethanol and oil is a method for producing ethanol by saccharification, fermentation, and distillation of leftover food. In this method, a three-phase centrifuge for performing separation into three phases of an oil component, an aqueous solution component, and a solid component is used in a step of solid-liquid separation of any one of a saccharified liquid, a fermented liquid, and a distillation waste liquid.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS OF INCREASING DIHYDROXY ACID DEHYDRATASE ACTIVITY TO IMPROVE PRODUCTION OF FUELS, CHEMICALS, AND AMINO ACIDS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034666.html</link>
            <description><![CDATA[The present invention is directed to recombinant microorganisms comprising one or more dihydroxyacid dehydratase (DHAD)-requiring biosynthetic pathways and methods of using said recombinant microorganisms to produce beneficial metabolites derived from said DHAD-requiring biosynthetic pathways. In various aspects of the invention, the recombinant microorganisms may be engineered to overexpress one or more polynucleotides encoding one or more Nfs1 proteins or homologs thereof and/or one or more polynucleotides encoding one or more Isd11 proteins or homologs thereof. In some embodiments, the recombinant microorganisms may comprise a cytosolically localized DHAD enzyme. In additional embodiments, the recombinant microorganisms may comprise a mitochondrially localized DHAD enzyme. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ENZYMATIC METHOD FOR PRODUCING ALDEHYDES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034665.html</link>
            <description><![CDATA[The invention relates to methods for producing aldehydes and the oxidation and reduction products thereof.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS TO PRODUCE ORGANIC COMPOUNDS FROM SYNTHESIS GASES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034664.html</link>
            <description><![CDATA[At least one isolated microorganism and a fermentation method to convert hydrogen gas, carbon dioxide gas, and/or carbon monoxide gas to a lower alkyl alcohol and/or carboxylic acid and to produce at least 2% by volume of the lower alkyl alcohol or carboxylic acid in an aqueous-based medium.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND SYSTEMS FOR BIOMASS CONVERSION TO CARBOXYLIC ACIDS AND ALCOHOLS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034663.html</link>
            <description><![CDATA[The disclosure includes a method, process and apparatus for the conversion of biomass to carboxylic acids and/or primary alcohols. The system may include a pretreatment/fermentation subsystem operable to produce a fermentation broth containing carboxylic acid salts from biomass, such as lignocellulosic biomass. The system may also include a dewatering subsystem operable to remove excess water from the fermentation broth to produce a concentrated product. The system may also includes an acid springing subsystem operable to produce a mixed carboxylic acid product. The system may also include a hydrogenation subsystem operable to produce an alcohol mixture, such as a mixture containing primary alcohols. Methods of operating this system or other systems to obtain a carboxylic acid or alcohol mixture are also provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[CO-CULTURING ALGAL STRAINS TO PRODUCE FATTY ACIDS OR HYDROCARBONS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034662.html</link>
            <description><![CDATA[The present invention provides methods and compositions for production of algal-based medium chain fatty acids and hydrocarbons.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[STRAINS FOR THE PRODUCTION OF FLAVONOIDS FROM GLUCOSE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034661.html</link>
            <description><![CDATA[The invention relates to the production of flavonoids and flavonoid precursors in cells through recombinant expression of tyrosine ammonia lyase (TAL), 4-coumarate:CoA ligase (4CL), chalcone synthase (CHS), and chalcone isomerase (CHI).]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034660.html</link>
            <description><![CDATA[A process for producing optically active succinimide derivatives as key intermediates of (3R)-2′-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4′(1H)-pyrrolo[1,2-a]pyrazine}-1′,2,3′,5(2′H)-tetraone, which comprises the following reaction steps.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[NEUTRAL pH SACCHARIFICATION AND FERMENTATION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034659.html</link>
            <description><![CDATA[Embodiments of the present disclosure relate to a process for producing downstream products, such as fermentable sugars and end products, from a starch substrate by saccharification and/or fermentation. The saccharification is effectively catalyzed by a glucoamylase at a pH in the range of 5.0 to 8.0. At a pH of 6.0 or above, the glucoamylase possesses at least 50% activity relative to its maximum activity. The saccharification and fermentation may be performed as a simultaneous saccharification and fermentation (SSF) process.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for Creating Color Variation in Anthocyanins Produced by Cell Culture]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034658.html</link>
            <description><![CDATA[Disclosed are methods for obtaining blue anthocyanin pigments and compositions including such pigments. This blue anthocyanin is present at an acidic pH (where anthocyanins are most stable) and may be used as a natural color additive. The methods can include cultivating a plant callus from a plant capable of producing anthocyanin in which the callus is treated with a blue anthocyanin-generating agent at a concentration sufficient to generate callus with blue anthocyanin pigments. The method can also include recovering the blue anthocyanin pigments from the culture. In an example, the blue anthocyanin-generating agent is ammonium molybdate.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[THROMBOPOIETIC COMPOUNDS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034657.html</link>
            <description><![CDATA[The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Neutralising Antibody Molecules Having Specificity for Human IL-17]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034656.html</link>
            <description><![CDATA[The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[FSH PRODUCING CELL CLONE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034655.html</link>
            <description><![CDATA[The present invention relates to nucleic acid molecules comprising a nucleic acid sequence coding for the α- and the β-chain of the human follicle stimulating hormone (FSH), respectively, which has been modified with respect to the codon usage in CHO cells. The present invention further relates to a recombinant nucleic acid molecule comprising such nucleic acid sequences and host cells containing such recombinant nucleic acid molecules, as well as their use in the production of recombinant human FSH. Finally, the present invention also relates to a method for producing host cells expressing human follicle stimulating hormone by transfecting cells in suspension culture under serum-free conditions with the recombinant nucleic acid molecule of the present invention.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR TRANSFORMING SCHIZOSACCHAROMYCES POMBE, TRANSFORMANT OF SCHIZOSACCHAROMYCES POMBE AND METHOD FOR PRODUCING HETEROLOGOUS PROTEIN]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034654.html</link>
            <description><![CDATA[To provide a method for transforming S. pombe for creating a transformant with a high stability of maintenance after passage and enables the steady production of a heterologous protein of interest, a transformant produced by the method and a method for producing a heterologous protein using the resultant transformant. A method for transforming Schizosaccharomyces pombe by using a vector carrying an expression cassette (containing a promoter capable of functioning in Schizosaccharomyces pombe, a heterologous protein structural gene and a terminator), and having recombination region(s) at which homologous recombination with each chromosome of Schizosaccharomyces pombe is to be achieved, which comprises integrating the expression cassette into the Tf2 transposon gene position(s) in the chromosome(s) of Schizosaccharomyces pombe by homologous recombination, a transformant created by the method and a method for producing a heterologous protein using the resultant transformant.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Trophic Conversion of Obligate Phototrophic Algae Through Metabolic Engineering]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034653.html</link>
            <description><![CDATA[Most microalgae are obligate photoautotrophs and their growth is strictly dependent on the generation of photosynthetically-derived energy. In this study it is shown that the microalga Phaeodaclylurn tricornutum can be engineered to import glucose and grow in the dark through the introduction of genes encoding glucose transporters. Both the human and Chlorella kessleri glucose transporters facilitated the uptake of glucose by P. tricornutum, allowing the cells to metabolize exogenous organic carbon and thrive, independent of light. This is the first successful trophic conversion of an obligate photoautotroph through metabolic engineering, and it demonstrates that methods of cell nourishment can be fundamentally altered with the introduction of a single gene. Since strains transformed with the glucose transport genes are able to grow non-photosynthetically, they can be exploited for the analysis of photosynthetic processes through mutant generation and characterization. Finally, this work also represents critical progress toward large-scale commercial exploitation of obligate phototrophic algae through the use of microbial fermentation technology, eliminating significant limitations resulting from light-dependent growth.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method for the Targeted Integration of Multiple Copies of a Gene of  Interest in a Yarrowia Strain]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034652.html</link>
            <description><![CDATA[This invention concerns a method for the targeted integration of at least three copies of a gene of interest in the genome of a Yarrowia strain including the steps of: (a) cultivating a Yarrowia strain, said strain including a deletion among at least three genes, the phenotype associated with each of these deletions corresponding to an auxotrophy or to a dominant character for this strain; (b) transforming said Yarrowia strain thus obtained with at least three recombinant vectors that include selection markers allowing, for this strain, the complementation of auxotrophy and, potentially, of the dominant character resulting from each of these deletions; and (c) selecting, on a minimum medium, the yeasts having integrated said at least three recombinant vectors. This invention also includes a method for producing a polypeptide of interest using this method as well as a method for obtaining a modified Yarrowia strain including a deletion among at least three genes, the phenotype associated with each of these deletions corresponding to an auxotrophy or to a dominant character for this strain.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Akt activity specifically inhibiting polypeptide]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034651.html</link>
            <description><![CDATA[The present invention is to provide a polypeptide specifically inhibiting the activity of Akt (Protein Kinase B), the DNA thereof, the antibody thereof, an inhibitor of Akt activity or an antitumor agent, and the like. The polypeptide comprises polypeptides (SEQ ID NO: 1, 3, 5, 7, and 9 of the sequence listing) that contain an amino acid sequence corresponding to any of the position of amino acid residue 10-24 of human TCL1, amino acid residue 8-22 of human TCL1B, amino acid residue 5-19 of human MTCP1, and amino acid residue 9-24 of mouse or rat TCL1; and the derivatives. Further, the present invention includes DNA encording the polypeptide (SEQ ID NO: 2, 4, 6, 8 or 10 of the sequence listing), and the antibodies specifically binding to the polypeptides. The polypeptide of the present invention can be used for an inhibitor of Akt activity, an antitumor agent, or the like.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034650.html</link>
            <description><![CDATA[The present invention relates to the provision of a polynucleotide comprising one or more functional fragments of a biosynthetic gene cluster involved in the production of a compound of formula (I) or (I′). The present invention also provides a method of preparing a compound of formula (I) or (I′) or of formula (II) to (VII), (XI) to (XIV) and (XVII) and (XVIII). Moreover, the use of such compound as a pharmaceutical composition is also provided in the present invention.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MICROORGANISM AND METHOD FOR PRODUCING CANTHAXANTHIN]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034649.html</link>
            <description><![CDATA[A carotenoid producing bacterium belonging to the genus Paracoccus that selectively produces canthaxanthin so that the amount thereof is not less than 90 percent by weight of the total amount of produced carotenoids including β-carotene, β-cryptoxanthin, echinenone, canthaxanthin, 3-hydroxyechinenone, 3′-hydroxyechinenone, zeaxanthin, phoenicoxanthin, adonixanthin, and astaxanthin. A method for producing canthaxanthin by culturing the above bacterium, and then collecting carotenoids from bacterial cells or a culture solution after the culturing.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PENTOSE SUGAR FERMENTING CELL]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034648.html</link>
            <description><![CDATA[The invention relates to a cell which comprises a nucleotide sequence encoding a xylose isomerase, wherein the amino acid sequence of the xylose isomerase has at least about 70% sequence identity to the amino acid sequence set out in SEQ ID NO: 3 and wherein the nucleotide sequence is heterologous to the host. A cell of the invention may be used in a process for producing a fermentation product, such as ethanol. Such a process may comprise fermenting a medium containing a source of xylose with a cell of the invention such that the cell ferments xylose to the fermentation product.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD AND APPARATUS FOR AUTOMATED WHOLE BLOOD SAMPLE ANALYSES FROM MICROSCOPY IMAGES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034647.html</link>
            <description><![CDATA[A method and apparatus for identifying one or more target constituents (e.g., white blood cells) within a biological sample is provided. The method includes the steps of: a) adding at least one colorant to the sample; b) disposing the sample into a chamber defined by at least one transparent panel; c) creating at least one image of the sample quiescently residing within the chamber; d) identifying target constituents within the sample image; e) quantitatively analyzing at least some of the identified target constituents within the image relative to one or more predetermined quantitatively determinable features; and f) identifying at least one type of target constituent within the identified target constituents using the quantitatively determinable features.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DETECTION OF H. PYLORI UTILIZING UNLABELED UREA]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034646.html</link>
            <description><![CDATA[Disclosed is a method and device for detection of H. Pylori in breath emissions utilizing an unlabelled urea, in which a patient ingests a safe quantity of unlabelled urea. After ingestion, expired breath of the patient is analyzed for ammonia, with a detection based on levels of ammonia lower than 50 parts per billion to 500 ppm to detect helicobacter pylori.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD AND APPARATUSES FOR CONDUCTING ASSAYS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034645.html</link>
            <description><![CDATA[Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[IDENTIFYING MATERIAL FROM A BREAST DUCT]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034644.html</link>
            <description><![CDATA[Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[FLUORESCENT PROTEIN]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034643.html</link>
            <description><![CDATA[An object of the present invention is to provide a red or orange fluorescent protein, which is characterized in that the difference (stokes shift) between an excitation peak value (wavelength of maximum absorption) and a fluorescence peak value (wavelength of maximum fluorescence) is greatened, so that the maximum fluorescence can be obtained by the maximum excitation. The present invention provides a novel fluorescent protein monomerized by introducing a mutation into a florescent protein derived from Fungia sp., and a novel chromoprotein and fluorescent protein derived from Montipora. sp.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR OBTAINING A SINGULAR CELL MODEL CAPABLE OF REPRODUCING IN VITRO THE METABOLIC IDIOSYNCRASY OF HUMANS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034642.html</link>
            <description><![CDATA[The method is based on the use of expression vectors coding for the sense and anti-sense mRNA of the Phase I and Phase II drug biotransformation enzymes showing a greatest variability in humans for transforming cells expressing reductase activity. Such vectors can modulate (increase or decrease) the individualized expression of an enzyme without affecting the other enzymes. This singular cell model can reproduce in vitro the metabolic idiosyncrasy of humans. It is applicable in the study of development of new drugs, specifically in the study of metabolism, potential idiosyncratic hepatotoxicity, medicament interactions, etc., of new drugs.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[BIOLOGICAL INFORMATION ACQUISITION METHOD]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034641.html</link>
            <description><![CDATA[A biological information acquisition method includes: measuring an amount of nicotinamide metabolite in a sample collectable from a living organism in a minimally invasive manner; and acquiring information concerning the living organism based on the measured amount of nicotinamide metabolite.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Isotonic Buffered Composition and Method that Enables Counting of Cells]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034640.html</link>
            <description><![CDATA[The present invention discloses multi-purpose metering fluid/rinse reagents for use in automated cellular analyzers that use liquid volumetric metering. The compositions contain a chelating agent, an ionizing salt, optionally a stabilizing ion, a buffer, a non-hemolytic surfactant, and optionally an antimicrobial agent. Advantageously, the compositions produce less than one part-per-million of formaldehyde over the course of one year. Methods for using the compositions are also described.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ANALYTE DETECTION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034639.html</link>
            <description><![CDATA[The present invention relates to analyte detection test systems, including test systems for the oral detection of analytes in saliva. The present invention also provides compositions and methods for storing multiple assay tests and compositions and methods for measuring the concentration of analytes in a sample.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Electrochemical assay for the detection of enzymatically active PSA]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034638.html</link>
            <description><![CDATA[The present invention is directed to the diagnosis of cancer associated with enzymatically active PSA in samples.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DETECTION OF TRICHOMONAS AND CANDIDA]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034637.html</link>
            <description><![CDATA[The invention relates to a method and a kit for the detection of Trichomonas infection by detecting N-acetyl-β-D-hexosaminidase activity. The invention also relates to a method and a kit for selective detection of presence of Trichomonas or Candida infection.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[CHEMICAL SENSING DEVICE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034636.html</link>
            <description><![CDATA[This invention relates to a chemical sensing device for detecting an analyte. The device comprises a light source, at least one luminescent reagent which is capable of luminescing when irradiated by the light source wherein the luminescence of the luminescent reagent is modifiable by the analyte thereby changing the generation of heat, which change in heat generation is proportional to the concentration of the analyte, a transducer having a pyroelectric or piezoelectric element and electrodes which is capable of transducing the change in heat to an electrical signal, and a detector which is capable of converting the electrical signal into an indication of the concentration of the analyte. The invention also relates to a method for detecting an analyte.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR AMPLIFYING ADENOSINE TRIPHOSPHATE AND METHOD AND REAGENT FOR DETECTING THE CONCENTRATION OF MICROORGANISMS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034635.html</link>
            <description><![CDATA[A method for amplifying adenosine triphosphate is provided, including mixing adenosine triphosphate sulfurylase, adenosine 5′ phosphosulfate, adenylate kinase, uridine triphosphate, acetate kinase, acetyl phosphate, luciferin and luciferase in the presence of ATP to form a mixture, and reacting the mixture to amplify ATP. A method and reagent for detecting a concentration of microorganisms are also provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MODIFIED LUCIOLA CRUCIATA LUCIFERASE PROTEIN]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034634.html</link>
            <description><![CDATA[A codon optimized and stabilized luciferase gene based upon the sequence of the natural luciferase gene isolated from Luciola cruciata (Japanese firefly) and a novel recombinant DNA characterized by incorporating this new gene coding for a novel luciferase into a vector DNA for improved activities in mammalian cells, are disclosed. This new luciferase exhibits long-wavelength light emission, as well as improved thermostability and higher expression levels in mammalian cell systems, compared to native luciferase.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MAGNETIC IMMUNOSENSOR AND METHOD OF USE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034633.html</link>
            <description><![CDATA[The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[TWO-PHASE OPTICAL ASSAYS FOR ANALYTES OF NO INTRINSIC OPITCAL CONTRAST]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034632.html</link>
            <description><![CDATA[Methods and kits for performing a two-phase optical assay for one or more than one analyte without intrinsic optical contrast in a sample are disclosed. The method requires use of a functionalized microparticle immobilized with two or more than functional components and an additional set of one or more than one functional component. The assay can be performed in one single container and does not need a wash step.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTI-LYSOPHOSPHOLIPID ANTIBODY DESIGN USING ANTIBODY STRUCTURES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034631.html</link>
            <description><![CDATA[The present invention provides crystalline forms of an anti-LPA antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided, as are methods of using structural information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Optimized variant anti-LPA antibodies are also provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Circovirus Sequences Associated With Piglet Weight Loss Disease (PWD)]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034630.html</link>
            <description><![CDATA[The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PREDICTION OF NON-FATAL AND FATAL ATHEROTHROMBOTIC EVENTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034629.html</link>
            <description><![CDATA[The present invention relates to methods and systems for the prediction of atherothrombotic events in human subjects. Preferably the human subjects are afflicted with a cardiovascular disease, such as end-stage renal disease. Methods and systems of the invention are particularly suited to predict atherothrombotic events in patients on hemodialysis.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[STANDARDIZED EVALUATION OF THERAPEUTIC EFFICACY BASED ON CELLULAR BIOMARKERS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034628.html</link>
            <description><![CDATA[The present invention provides materials and methods for predicting the response of a disease state to a therapeutic agent. A targeting moiety specific for a biological marker is labeled with a reporter moiety and used to analyze cells characteristic of the disease state. The output of the reporter moiety, which may be fluorescence intensity, is compared to the output of reference standard analyzed under similar or identical conditions. The use of a reference standard allows biomarker reporting to be normalized. Biomarker values can then be correlated from sample to sample and from laboratory to laboratory based on quantitative calibration on a universal reference standard.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Diagnosis of benign and cancerous growths by measuring circulation tumor stem cells and serum annexina2]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034627.html</link>
            <description><![CDATA[Provided herein is a method for diagnosing/prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Neoplasia-Specific Autoantibodies and Methods]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034626.html</link>
            <description><![CDATA[ENOX2 proteins are growth-related cell surface proteins expressed specifically by cancer cells; they catalyze NADH oxidation and protein disulfide-thiol interchange reactions. Taught herein are IgM class autoantibodies specific to ENOX2 (tNOX) in a variety of cancer patient sera. Early cancer patients produce these autoantibodies as a possible defense mechanism. Because ENOX2 is bound to autoantibodies in patients, it is unavailable to bind conventional ENOX2-specific antibodies in standard ELISA assays, but two-dimensional gel electrophoresis dissociates ENOX2 protein from autoantibodies, allowing detection. Probing ENOX2 using cancer sera as a source of ENOX2 autoantibodies followed by horseradish peroxidase-coupled anti-human IgM allows visualization and detection of the ENOX2 autoantibody. ENOX2 autoantibodies from breast cancer sera reacts with the ENOX2 isoforms from, e.g., lung and ovarian cancer patient sera. ENOX2 autoantibodies enable cancer screening based both on autoantibody detection and autoantibody dissociation to allow for standard ELISA development as well as therapy.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Monoclonal Antibody Capable of Binding Integrin Alpha 10 Beta 1]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034625.html</link>
            <description><![CDATA[The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen and Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[OSCILLATING IMMUNOASSAY METHOD AND DEVICE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034624.html</link>
            <description><![CDATA[The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[UP-CONCENTRATION OF ORGANIZ MICROOBJECTS FOR MICROSCOPIC IMAGING]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034623.html</link>
            <description><![CDATA[A method of analyzing a sample fluid containing organic microobjects is proposed. The method comprises the steps of: up-concentrating (S1) the microobjects by removing, in a total time T1, a volume V1 of the sample fluid from the upconcentrate sample microobjects; immersing (S2) the microobjects in a transfer fluid, or leaving the microobjects in a remaining portion of the sample fluid, the remaining portion of the sample fluid then providing the transfer fluid; filtering (S3), in a total time T3, a volume V3 of the transfer fluid by a filter, thereby accumulating the microobjects on the filter; and generating (S4) an image of the microobjects accumulated on the filter; wherein the throughput V1/T1 of the step of up-concentrating (S1) is greater than the throughput V1/T1, of the step of filtering (S3). The filter may be a second filter, and the step of up-concentrating (S1) may involve: filtering the sample fluid by a first filter, thereby accumulating the microobjects on the first filter. An apparatus or system for analyzing a sample fluid containing organic microobjects is also disclosed.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ACTIVATION AND MONITORING OF CELLULAR TRANSMEMBRANE POTENTIALS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034622.html</link>
            <description><![CDATA[The use of nanostructures to monitor or modulate changes in cellular membrane potentials is disclosed.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MICROORGANISM CONCENTRATION PROCESS AND DEVICE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034621.html</link>
            <description><![CDATA[A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration device comprising a sintered porous polymer matrix comprising at least one concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration device with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration device.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS AND METHODS FOR ADHESION OF INTACT CELLS TO AN APPARATUS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034620.html</link>
            <description><![CDATA[Bio-adhesive compositions that include an extra-cellular matrix protein, bovine serum albumin conjugated with a fluorophore, and an aggregate are provided. The bio-adhesive composition may also include at least one component selected from the group consisting of collagen type IV, laminin, and chitosan. Also provided are methods of making the present compositions, that include taking a desired amount of extracellular matrix gel to liquid form of extracellular matrix; adding a desired amount of bovine serum albumin conjugated with a fluorophore; adding a desired amount of aggregate; and mixing. Further provided are methods for attaching cells to an apparatus using the present bio-adhesive compositions, and methods of attaching the present bio-adhesive compositions to an apparatus. Also provided are kits that include the present composition, components thereof or apparatuses, having the present composition attached thereto.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD OF DETERMINING THE OLIGOMERIC STATE OF A PROTEIN COMPLEX]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034619.html</link>
            <description><![CDATA[A method of counting protein subunits to determine the oligomeric state of an oligomeric protein complex includes tagging and expressing the protein subunits with a mass/charge tag and selectively removing each mass/charge tag. The number of protein subunits of the oligomeric complex corresponds to the number of mass/charge tags removed.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR CULTURE AND PRODUCTION OF SINGLE CELL POPULATIONS OF HUMAN EMBRYONIC STEM CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034618.html</link>
            <description><![CDATA[We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ASSAYS FOR BACTERIAL DETECTION AND IDENTIFICATION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034617.html</link>
            <description><![CDATA[The invention herein generally relates to kits and methods for detecting the presence of a bacterium in a subject, for example, methicillin resistant S. aureus. In certain embodiments, the invention provides a method of detecting presence of a bacterium in a sample from a subject, the method including: contacting a sample from a subject with a bacterium-specific lytic enzyme or lysostaphin capable of specific lysis of a first bacterium if present in the sample, thereby exposing an intracellular gene or gene product of the first bacterium; contacting the sample with a particle having a protein on a surface of the particle in a presence of an antibody in which an Fc portion specifically binds the protein and an F(ab)2 portion specifically binds the intracellular gene or gene product of the first bacterium, with the proviso that when the particle is a second bacterium, the second bacterium is different from the first bacterium; and detecting the presence or absence of the first bacterium by observing the sample for an agglutination reaction, wherein agglutination indicates the presence of the first bacterium in the sample.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method for Modulating Epithelial Stem Cell Lineage]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034616.html</link>
            <description><![CDATA[The present invention relates to methods of modulating epithelial stem cell lineage by regulating the expression of Lef1 or a BMP inhibitor and/or the stability of β-catenin or the expression of a Wnt; regulating the expression or activity of GATA-3; or regulating BMPR1A activity either at the level of receptor expression or at the level of pathway activation. Methods of regulating E-cadherin, GATA-3, BMPR1A and HK1-hair keratin and methods of identifying agents which modulate the epithelial stem cell lineage are further provided. Such agents are useful for inhibiting or stimulating inner root sheath development or hair follicle formation.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[HIFU INDUCED CAVITATION WITH REDUCED POWER THRESHOLD]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034615.html</link>
            <description><![CDATA[An apparatus for irradiating a liquid sample with acoustic energy to generate cavitation in the liquid sample is provided. The apparatus includes a source and is adapted to receive a cartridge in such a way, that the apparatus focuses the HIFU waves emitted from the source onto a liquid air interface that is present within the cartridge. This focusing is performed when the cartridge is inserted into a receiving section of the apparatus.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[EARLY DETECTION OF PATHOGENS IN BLOOD]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034614.html</link>
            <description><![CDATA[The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na3PO4.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034613.html</link>
            <description><![CDATA[The disclosure is directed to apparatus and methods for testing relationships between gene expression and physical appearance of skin and methods of assessing the efficacy of skin anti-aging agents.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods and Kits for miRNA Isolation and Quantitation]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034612.html</link>
            <description><![CDATA[The present invention is a kit and method for isolating and quantitating miRNA and to the use of such methods in the diagnosis and prognosis of disease.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR DETECTING PRESUMED IGA NEPHROPATHY AND METHOD FOR SCREENING IGA NEPHROPATHY PATIENTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034611.html</link>
            <description><![CDATA[Based on detection of Treponema bacteria or Campylobacter bacteria present in a sample derived from the tonsil of a subject who has a positive result on at least one of a urinary protein test and a urinary occult blood test, or of a patient diagnosed with possible IgA nephropathy, presumed IgA nephropathy can be detected with a high accuracy, in a simple and quick manner without physical burden on subjects. Also, an IgA nephropathy patient for whom tonsillectomy is effective in therapy of IgA nephropathy can be selected with a high accuracy, in a simple and quick manner without physical burden on subjects.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[IDENTIFICATION OF TOXIN-BINDING PROTEIN INVOLVED IN RESISTANCE TO CRY1 TOXINS, AND RELATED SCREENING METHODS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034610.html</link>
            <description><![CDATA[The subject invention relates in part to the surprising and unexpected discovery that insects that are resistant to Bacillus thuringiensis Cry toxins have measurably altered alkaline phosphatase (ALP) activity as compared to insects that are susceptible to Cry toxins. This and other surprising discoveries reported herein have broad implications in areas such as managing and monitoring the development of insect resistance to B. t. toxins. For example, the subject invention provides a simple and fast assay (enzymatic or otherwise) for detecting ALP activity levels and thereby monitoring the development of resistance by insects to crystal protein insect toxins. There was no prior motivation or suggestion to go about resistance monitoring using this simple and easy approach.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034609.html</link>
            <description><![CDATA[The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MICRORNA AS A BIOMARKER OF PANCREATIC ISLET BETA-CELL ENGAGEMENT]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034608.html</link>
            <description><![CDATA[MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic β-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on β-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating β-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations. Because the expression of these miRNAs is not affected by glucose, fatty acid, insulin, or β-cell function, monitoring miR-132 and miR-212 expression can be used to monitor the efficacy of any agent that effects an increase cAMP in β-cells. Such agents include for example, GLP-1, glucagon, GPR-119, and GIP receptor agonists; dipeptidyl peptidase IV (DPP IV) inhibitors; and phosphodiesterase inhibitors.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods and apparatus for measuring analytes using large scale fet arrays]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034607.html</link>
            <description><![CDATA[Methods and apparatus relating to very large scale FET arrays for analyte measurements. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. In one example, chemFET arrays facilitate DNA sequencing techniques based on monitoring changes in hydrogen ion concentration (pH), changes in other analyte concentration, and/or binding events associated with chemical processes relating to DNA synthesis.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DETECTION OF SALMONELLA ENTERICA SUBSPECIES ENTERICA SEROVAR ENTERITIDIS IN FOOD AND ENVIRONMENTAL SAMPLES, METHODS AND COMPOSITIONS THEREFOR]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034606.html</link>
            <description><![CDATA[Embodiments of the disclosure relate to compositions of isolated nucleic acid sequences, methods, workflows and kits of use thereof for detection of Salmonella enterica, subspecies enterica, serovar Enteritidis (S. Enteritidis) in a sample, particularly in a food (egg, poultry) or environmental sample (including poultry-related environmental samples). Embodiments of the disclosure may also be used to differentially detect S. Enteritidis without cross-reacting with S. Paratyphi C or other closely related Salmonella species. In some embodiments, methods and kits of the disclosure may comprise a TaqMan® assay. Following sample enrichment, methods of detection may be completed in approximately 3 hours.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR DETECTION OF COLORECTAL TUMOR]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034605.html</link>
            <description><![CDATA[Disclosed is a method for determining the presence or absence of a colorectal tumor, specifically colorectal cancer or colorectal adenoma, with high sensitivity and high specificity by employing the methylation of DNA as a measure. Also disclosed is a kit for carrying out the method. Specifically, measurement is made on the degree of methylation of one or more CpG sequences contained in the region lying between positions -477 to -747, more preferably a CGCG sequence contained in the region lying between positions -688 to -691, in TWIST1 gene (Homo sapiens twist homolog 1; Drosophila gene) located on the genome sequence of a test cell.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034604.html</link>
            <description><![CDATA[The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[LIGATION-BASED DETECTION OF GENETIC VARIANTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034603.html</link>
            <description><![CDATA[The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Recombinant Polymerases For Improved Single Molecule Sequencing]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034602.html</link>
            <description><![CDATA[Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing. Such properties can include enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased thermostability, increased accuracy, increased speed, increased readlength, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Porous Materials for Biological Sample Collection]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034601.html</link>
            <description><![CDATA[Methods, apparatuses, and systems for collecting samples using hybrid porous materials that include an organic material and an inorganic material. A method for sample collection includes contacting a hybrid porous material and a biological sample to the porous material. The hybrid porous material includes an inorganic material and an organic material. The method includes placing the porous material with the attached sample in a liquid medium, wherein the sample is separated from the porous material in the liquid medium to form a separated sample, and collecting the separated sample in the medium.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034600.html</link>
            <description><![CDATA[Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SCREENING SYSTEMS UTILIZING RTP801]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034599.html</link>
            <description><![CDATA[RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Real-Time Detection of Influenza Virus]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034598.html</link>
            <description><![CDATA[The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS OF MONITORING TREATMENT OF AVIREMIC HIV-INFECTED PATIENTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034597.html</link>
            <description><![CDATA[Methods of monitoring the efficacy of intensified highly active anti-retroviral therapy (HAART) treatment in aviremic Human Immunodeficiency Virus (HIV)-infected patients.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DEVICE FOR AUTOMATICALLY CULTIVATING CELLS IN PARALLEL]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034596.html</link>
            <description><![CDATA[A device for automatically cultivating cells in parallel in cell culture vessels, in particular microtiter (MT) plates (2), having a housing (23) in which are disposed an observation unit (3) comprising at least one microscope (7) and at least one camera (6), a receptacle device (4) for receiving the cell culture vessels, and a fluid distribution unit (5) for automatically filling and/or emptying the cell culture vessels, in particular the wells (17) of microtiter (MT) plates (2), with fluid, wherein the climatic conditions in the device, in particular the gas composition and temperature, can be controlled in a closed loop at least in the region of the cell culture vessels, wherein a climate chamber (21) is provided in the housing, in which a desired temperature and/or a particular gas composition can be adjusted automatically, and in which the receptacle device (4); having the cell culture vessels (2) is at least partially integrated.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Enriched stem cell and progenitor cell populations, and methods of producing and using such populations]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034595.html</link>
            <description><![CDATA[The present invention provides a novel method to isolate and expand pure progenitor/stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor/stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor/stem cells, e.g., cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methylocystis Strain SB2 Materials and Methods]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034594.html</link>
            <description><![CDATA[The present disclosures provides isolated or purified compounds, each of which bind to a metal atom. Generally, the compounds are small in size (e.g, molecular weight of less than about 1 kDa) and peptidic in nature, inasmuch as the compounds comprise amino acids. In some embodiments, the compound comprises a structure of Formula I: M1-P1-M2-P2 wherein each of P1 and P2 is a peptide comprising at least two amino acids, M1 is a first metal binding moiety comprising a substituted imidazolone ring, M2 is a second metal binding moiety comprising a substituted oxazolone ring, and wherein M1 and M2 bind to a single metal atom. Also provided are related complexes, conjugates, cells which synthesize the compounds of the present disclosures, substantially homogenous cultures thereof, kits and compositions, and methods of making or using the materials of the present disclosures.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[CYCLIC PEPTIDES WITH AN ANTI-PARASITIC ACTIVITY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034593.html</link>
            <description><![CDATA[The present invention relates to a method for preparing a cyclic peptide with antiparasite activity and anticancer activity. The invention also relates to this peptide as an antiparasite agent, for example in the treatment of toxoplasmosis and as an anticancer agent. The invention also relates to the use of this cyclic peptide for treating organs ex vivo before transplantation.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[BIOREACTORS COMPRISING FUNGAL STRAINS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034344.html</link>
            <description><![CDATA[Disclosed herein are compositions comprising an isolated cellulose degrading fungus. Also disclosed are culture compositions and bioreactor compositions comprising the cellulose degrading fungus. Further described herein are filtration and extraction devices comprising the cellulose degrading fungus. Still further disclosed are bioprocessing facilities for and methods for producing co-products resulting from one or more bioprocesses of the cellulose degrading fungus.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PREVENTION OF EXTRACT DARKENING AND MALODOR FORMATION DURING SOLUBILIZATION OF PLANT CELL WALL MATERIAL]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034343.html</link>
            <description><![CDATA[The present invention relates to methods for reducing color and/or unpleasant taste and/or malodor development in a composition comprising at plant material, such a ceral bran, in particular during solubilization processes of the plant material. The invention further relates to optimised methods of solubilization, wherein color and/or unpleasant taste and/or malodor development is controlled. Solubilised plant material, kit of parts, the use of such solubilised plant material, e.g. in food products or bioethanol are also encompassed by the present invention.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR OBTAINING A PREPARATION OF BETA-AMYLASES FROM THE SOLUBLE FRACTIONS OF STARCH PLANTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034342.html</link>
            <description><![CDATA[The present invention relates to a method for obtaining a preparation of β-amylases from the soluble fraction of starch plants, characterized in that the soluble fraction of starch plants is selected from the group consisting of the soluble fractions of wheat, pea, broad bean, horse bean, rice, barley, rye, buckwheat, potato and sweet potato, and preferably of wheat and barley, a clarification of said soluble fractions is carried out in such a way as to remove therefrom the insoluble substances and the colloids and, optionally, an ultrafiltration of said clarified soluble fractions is carried out in such a way as to obtain an ultrafiltration retentate containing the concentrated β-amylase and an ultrafiltration permeate, said ultrafiltration retentate containing the concentrated β-amylase is diafiltered and the resulting β-amylase is recovered.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS OF MICROBIC BIOTECHNOLOGY FOR COMPLETELY DEGRADING GLUTEN IN FLOURS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034339.html</link>
            <description><![CDATA[The present invention concerns the use of lactic acid bacteria selected and fungal enzymes for the gluten complete degradation from both bread and durum wheat, barley, rye and oat flour. In particular, the invention concerns the use of lactic acid bacteria selected and fungal enzymes for the gluten complete degradation (residual gluten concentration lower than 20 ppm) of cereal flours, which after detoxification can be used according to a standardized biotechnological protocol for the production of various gluten-free foods.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DIAGNOSTIC METHOD USING PALB2]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034318.html</link>
            <description><![CDATA[The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Prediction of Response to Platinum-Based Therapy]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034317.html</link>
            <description><![CDATA[Method for determining whether a mammalian subject having a cancer belongs to a first or a second group, wherein subjects of the first group are more likely to respond to a platinum-based therapy than subjects of the second group, comprising the steps of: evaluating the amount of RBM3 protein or RBM3 mRNA present in at least part of a sample earlier obtained from said subject, and determining a sample value corresponding to said amount; comparing the sample value with a reference value; and, if said sample value is higher than said reference value, concluding that said subject belongs to a first group; and if said sample value is lower than or equal to said reference value, concluding that said subject belongs to a second group. There is further provided means useful in the establishment of a treatment prediction.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS FOR THE TREATMENT OF GLUTEN INTOLERANCE AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034299.html</link>
            <description><![CDATA[The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analogue or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[INACTIVATED VARICELLA ZOSTER VIRUS VACCINES, METHODS OF PRODUCTION, AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034267.html</link>
            <description><![CDATA[The invention provides an inactivated varicella zoster virus (VZV), and compositions and vaccines comprising said inactivated VZV, wherein the infectivity of the VZV is undetectable and wherein the inactivated VZV induces an immune response against VZV when administered to a patient. In embodiments of the compositions described herein, the VZV is inactivated with gamma radiation. The invention also provides a method of preparing an inactivated VZV vaccine, the method comprising gamma irradiating a sample comprising a VZV using from about 5 kGy to about 50 kGy of gamma radiation. Also provided by the invention herein is a method of treatment of or immunization against HZ or other disease associated with the reactivation of VZV, the method comprising administering to a subject a vaccine or pharmaceutical composition comprising a therapeutically effective amount of an inactivated VZV and a pharmaceutically acceptable carrier, wherein the VZV is inactivated by gamma irradiation.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034265.html</link>
            <description><![CDATA[Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034264.html</link>
            <description><![CDATA[Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SEQUENCES DIAGNOSTIC FOR SHRIMP PATHOGENS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034263.html</link>
            <description><![CDATA[Primers have been isolated that are diagnostic for the detection of the white spot syndrome virus (WSSV). The primers are based on a new portion of the WSSV genome and may be used in primer directed amplification or nucleic acid hybridization assay methods.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Bovine Herpes Virus-1 Compositions, Vaccines and Methods]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034262.html</link>
            <description><![CDATA[The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034261.html</link>
            <description><![CDATA[The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[HCV VACCINES AND METHODS FOR USING THE SAME]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034256.html</link>
            <description><![CDATA[Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTIGENIC CLOAKING AND ITS USE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034254.html</link>
            <description><![CDATA[Disclosed are antigens that include a target epitope that is defined by atomic coordinates of those amino acids of the antigen that contact an antibody of interest that specifically binds the antigen. The disclosed antigens have between about 10% and about 90% of surface exposed amino acid residues located exterior of the target epitope substituted as compared to a wild-type antigen and less than about 10% of the non-surface exposed amino acid residues substituted as compared to a wild-type antigen. Also disclosed are nucleic acids encoding these antigens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Influenza Vaccines, Antigens, Compositions, and Methods]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034253.html</link>
            <description><![CDATA[The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and compositions useful in inducing or enhancing an immune response agains influenza antigens. Provided are recombinant protein antigens, compositions, and methods for the production of such antigens in plants. In some embodiments, influenza antigens include hemagglutinin polypeptides, neuraminidase polypeptides, and/or combinations thereof.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER BY INDUCING DENDRITIC CELL-LIKE DIFFERENTIATION FROM MONOCYTES TO IMPROVE ANTICANCER IMMUNE ACTIVITY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034251.html</link>
            <description><![CDATA[According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or(b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034245.html</link>
            <description><![CDATA[Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034240.html</link>
            <description><![CDATA[The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PROTEINS WITH IMPROVED SOLUBILITY AND METHODS FOR PRODUCING AND USING SAME]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034239.html</link>
            <description><![CDATA[A method is provided for improving the solubility of proteins, for example, bacterial toxins. In one embodiment, solubility is improved by introducing point mutations that replace cysteine residues capable of forming intermolecular disulfide bonds with other amino acid residues that do not form such bonds. By abrogating the ability of the cysteine residues to form inter-molecular disulfide bonds, aggregation of the protein is reduced, thereby improving the solubility of the protein. In another embodiment, solubility of the protein is improved by producing truncated forms of the protein that express the LHN domain and a fragment of the Hc domain. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034237.html</link>
            <description><![CDATA[Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[CO-TARGETING OF AURORA A KINASE AND LIM KINASE 1 FOR CANCER THERAPY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034236.html</link>
            <description><![CDATA[Disclosed herein are therapies for treating or preventing reoccurrence of cancer. The therapies involved inhibition of LIMK1 in conjunction with AurKA inhibition. Specifically exemplified herein is the administration of an AurKA inhibitor in conjunction with a LIMK1 RNA interfering molecule.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Marker for Liver-Cancer Diagnosis and Recurrence and Survival Prediction, a Kit Comprising the Same, and Prognosis Prediction in Liver-Cancer Patients Using the Marker]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034235.html</link>
            <description><![CDATA[A composition for detecting a marker for the diagnosis or prognosis of liver cancer is disclosed. The composition includes an agent capable of assessing the expression level of UQCRH (ubiquinol-cytochrome c reductase hinge protein). In addition, a kit having the composition, a microarray for the diagnosis of liver cancer using the marker, and a method for detecting the marker, and predicting recurrence following surgery in liver cancer patients are disclosed. The marker is able to contribute to the early diagnosis of liver cancer and prediction of recurrence following surgery and survival of liver cancer patients who have undergone hepatic resection, and also is significant for being a promising therapeutic target for liver cancer.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR THE TREATMENT OR PREVENTION OF SYSTEMIC SCLEROSIS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034234.html</link>
            <description><![CDATA[The invention is in the field of molecular immunology, more in particular in the field of the prevention or treatment of autoimmune diseases, more in particular systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention therefore relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[TLR3 BINDING AGENTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034232.html</link>
            <description><![CDATA[The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034231.html</link>
            <description><![CDATA[The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE BACTERIA]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034230.html</link>
            <description><![CDATA[The invention provides protective antigens which are useful in vaccine compositions to induce protection against gram positive bacteria, particularly against S. agalactiae, S. pyogenes, S. pneumoniae, S. aureus, S. suis, and S. equi.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MONOCLONAL ANTIBODIES DIRECTED AGAINST LG4-5 DOMAIN OF ALPHA3 CHAIN OF HUMAN LAMININ-5]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034229.html</link>
            <description><![CDATA[The present invention relates to a monoclonal antibody binding to the LG4/5 domain of chain alpha3 of human protein laminin-5, wherein said monoclonal antibody inhibits the binding of syndecan-1 to said laminin-5 alpha3 chain LG4/5 domain, in particular 1H12 monoclonal antibody produced by the hybridoma cell line named 1H12 deposited on Jan. 8, 2008 at the C. N. C. M. under number 1-3890, as well as chimerized, humanized derivatives and fragments thereof, and nucleic acid sequences encoding them, as well as vectors and host cells expressing them. The invention further relates to the medical application of such antibodies, in particular for treating cancer.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034228.html</link>
            <description><![CDATA[The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DIAGNOSTIC METHOD OF SKIN INFLAMMATORY DISEASE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034226.html</link>
            <description><![CDATA[The invention provides a method of determining (or diagnosing) the presence or absence of a functional abnormality in the skin barrier, a kit therefor, a method of ameliorating a functional abnormality in the skin barrier based on the onset mechanism, and a drug therefor. The method of determining the presence or absence of a functional abnormality in the skin barrier comprises measuring the expression of a protease and/or an inhibitor thereof on the skin surface of a test object, and the like.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[T-Cell Receptor Antibodies And Methods of Use Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034221.html</link>
            <description><![CDATA[The present invention is directed to the production and use of monoclonal antibodies, or antigen binding fragments thereof, that specifically bind the T cell antigen receptor (TCR) and their use for immunomodulation. In preferred embodiments, the antibody or antigen binding fragment of the invention specifically binds the constant region of the α chain of the TCR, or otherwise specifically binds the α chain regardless of TCR clonal origin (i.e., is pan specific for TCR). The antibodies of the invention may be used, for example, in immunosuppressive therapies for transplant maintenance and the treatment of autoimmune diseases, and/or as targeting molecules for use in the treatment of T-cell malignancies.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[USES OF IL-23 AGONISTS AND ANTAGONISTS; RELATED REAGENTS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034219.html</link>
            <description><![CDATA[Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[RBM3 in Colorectal Cancer Prognostics]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034218.html</link>
            <description><![CDATA[The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTI-MST1R ANTIBODIES AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034215.html</link>
            <description><![CDATA[The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND KITS FOR DETERMINING THE PROGNOSIS OF PULMONARY SARCOIDOSIS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034214.html</link>
            <description><![CDATA[The invention provides a method for determining the prognosis of pulmonary sarcoidosis in an individual subject, comprising conducting gene expression analysis on a sample from the subject. The sample is obtained by bronchoscopy under procedural methods not requiring general anaesthesia.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034212.html</link>
            <description><![CDATA[The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[EGFR antibodies comprising modular recognition domains]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034211.html</link>
            <description><![CDATA[Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS FOR POTENTIATING APOPOSIS SIGNALS IN TUMOUR CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034210.html</link>
            <description><![CDATA[The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[PRODUCTION OF HER RECEPTOR ANTIBODIES IN PLANT]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034207.html</link>
            <description><![CDATA[A method of making an antibody in plants that binds to a HER receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[FERTILIZATION MODULATION COMPOUNDS AND PROCESS FOR IMPLEMENTING THEM]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034204.html</link>
            <description><![CDATA[This invention relates to fertilization modulation compounds and process for implementing them.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034202.html</link>
            <description><![CDATA[An ameliorating agent for chronic obstructive pulmonary disease (COPD) containing as an active ingredient a lecithinized superoxide dismutase represented by the following general formula (I): SOD′(Q-B)m (I) (in the formula SOD′ represents a residue of the superoxide dismutase; Q represents a chemical crosslinking; B represents a residue without a hydrogen atom of a hydroxyl group of lysolecithin having the hydroxyl group at the 2-position of glycerol; m is the average number of bonds of lysolecithin to one molecule of superoxide dismutase and represents an integer of 1 or more). The ameliorating agent for COPD is intravenously administered or inhalation-administrated.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MONOGASTRIC ANIMAL FEED]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034199.html</link>
            <description><![CDATA[The present invention relates an improved feed additive or food supplement formulation obtained from more than one strain of Lactic acid bacteria. The feed additive or supplements is used to feed monogastric animals such as avian, fowl. Moreover, the feed provides better growth and feed utilization for monogastric animals. Further, the animal feed can be used for controlling food intake in the animals.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[HIV-RESISTANT STEM CELLS AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034197.html</link>
            <description><![CDATA[Disclosed are recombinant stem cells that are resistant to HIV infection. Also disclosed are their uses in treating AIDS.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF (FRANK)]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034196.html</link>
            <description><![CDATA[The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Somatic Stem Cells]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034194.html</link>
            <description><![CDATA[A population of somatic stem cells and a method of preparing same. Also disclosed are two subpopulations thereof and their various uses.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS AND METHODS FOR ENHANCING CELL REPROGRAMMING]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034192.html</link>
            <description><![CDATA[The invention provides compositions and methods of use to enhance reprogramming of mammalian cells. Certain compositions and methods of the invention are of use to enhance generation of induced pluripotent stem cells by reprogramming somatic cells. Certain compositions and methods of the invention are of use to enhance reprogramming of pluripotent mammalian cells to a differentiated cell type. Certain compositions and methods of the invention are of use to enhance reprogramming of differentiated mammalian cells of a first cell type to differentiated mammalian cells of a second differentiated cell type. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that enhances or contributes to reprogramming mammalian cells. Certain of the inventive compositions and methods relate to inhibiting histone methylation.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[YEAST STRAINS AND THEIR USES IN THE PRODUCTION OF LIPIDS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034190.html</link>
            <description><![CDATA[The invention is directed to isolated microorganisms, as well as biomasses, cultures, microbial oils, and compositions thereof. The invention also provides methods of producing the microbial oils and methods of using the isolated microorganisms, biomasses, and microbial oils.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[MEANS AND METHODS FOR DURABLE INHIBITION OF PATHOGENS]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034189.html</link>
            <description><![CDATA[The invention provides improved nucleic acids for anti-HIV therapy. The invention further provides selection methods which are capable of predicting already at an early stage of development whether promising anti-pathogenic candidate compounds will be suitable for therapeutic use in vivo.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Akt Nucleic Acids, Polypeptides, and Uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034188.html</link>
            <description><![CDATA[The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTI-CD20 ANTIBODIES AND FUSION PROTEINS THEROF AND METHODS OF USE]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034185.html</link>
            <description><![CDATA[The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Isolated Monoclonal Antibody or Fragment Thereof Binding Prostate Specific Membrane Antigen, Conjugates and Uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034168.html</link>
            <description><![CDATA[An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[TYROSINE KINASE RECEPTOR TYRO3 AS A THERAPEUTIC TARGET IN THE TREATMENT OF CANCER]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034167.html</link>
            <description><![CDATA[The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[AMYLOID BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034166.html</link>
            <description><![CDATA[The invention relates to neuromodulatory oligomers of the amyloid-β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-β(1-42) proteins, the production and use thereof.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Fullerene Assisted Cell Penetrating Peptides]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034162.html</link>
            <description><![CDATA[A composition and method is described for intracellular delivery of fullerene containing peptides. The composition and method involve fullerene-substituted phenylalanine as part of a peptide based delivery system. The presence of a fullerene-substituted amino acid in a peptide is found to alter the intracellular transport properties of the peptide.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034160.html</link>
            <description><![CDATA[Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTIBODIES THAT BIND BOTH BCMA AND TACI]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034159.html</link>
            <description><![CDATA[Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor, and the B-cell maturation (BCMA) receptor.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Artificial cells]]></title>
            <link>http://www.freepatentsonline.com/y2012/0034157.html</link>
            <description><![CDATA[The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.]]></description>
            <pubDate>Thu, 09 Feb 2012 08:00:00 EST</pubDate>
        </item>
    </channel>
</rss>
